Any content you receive is for information purposes only. Always conduct your own research. *Disseminated on behalf of Optimi Health Corp.
Optimi Health Corp. (NASDAQ: OPTH) Just Landed Back On
The Street Ideas Watchlist This Morning
—Wednesday, July 1, 2026
Don’t Miss Our Next Update—Get Real-Time Alerts Sent Directly To Your Phone. Up To 10X Faster Than Email. Take a Look At (OPTH) While It’s Still Early…
July 1, 2026 Dear Reader, A U.S. Executive Order is accelerating FDA review of ps-ych-ede-lic therapies. One newly listed Nasdaq company is already manufacturing and shipping finished products to patients under regulated frameworks. On Monday, Optimi Health Corp. (Nasdaq: OPTH) completed its third commercial shipment of psi-locy-bin capsules to Australia — 1,000 doses of 5mg psi-locy-bin, now being prescribed to patients with treatment-resistant depression and reimbursed by four major public and private payers. That alone would be enough to put a name on our screen. But it is just one of five material announcements OPTH has made since June began. On June 8, the company secured naturally derived ibo-gaine supply from two sources and commenced finished product development at its GMP facility in British Columbia. On June 10, OPTH completed its first international shipment of psi-locy-bin to the United Kingdom for a planned Phase 2 clinical trial. On June 16, the company launched two new standardized microdose psi-locy-bin products — at 1mg and 2mg — designed for clinical research organizations. And on June 29, the third commercial Australia export was confirmed, with more than 750 clinicians now trained to deliver the therapy and no serious adverse events reported after two years of regulated use. These are exactly the reasons why OPTH is topping the Street Ideas radar this morning — Wednesday, July 1, 2026. 
Keep in mind, OPTH less than 5M shares listed as available to the public right now. When companies have small floats like this, the potential exists for big moves if demand begins to shift. That combination — a fresh Nasdaq listing, active commercial shipments, new analyst coverage, and a small public float — is exactly why OPTH deserves a closer look right now. This is not a company still trying to prove it can build compliant infrastructure; Optimi already has licensed facilities, regulated production, and commercial distribution underway. So before we get into the recent potential catalysts, here’s the foundation readers need to understand first. Inside Optimi Health
A licensed pharma manufacturer with commercial supply already underwayOptimi Health Corp. is a Canadian GMP-certified pharma manufacturer specializing in the regulated production and international export of M-D-M-A and Psi-locy-bin for prescription-based mental health therapies. Headquartered in Vancouver, British Columbia, the company operates two purpose-built 10,000-square-foot pharma-grade facilities in Princeton, B.C., where it holds a Health Canada Dr-ug Establishment Licence (DEL), GMP certification, a Dealer's Licence, and a Class A Precursor Licence. The company's vertically integrated platform spans licensed cultivation, extraction, formulation, encapsulation, quality control, and distribution. Its installed manufacturing capacity supports approximately 1 Mln M-D-M-A capsules and 1 Mln Psi-locy-bin capsules annually, sufficient to support more than 200,000 patients per year under episodic treatment models — all without incremental capital expenditure. OPTH is one of the only companies globally with both M-D-M-A and Psi-locy-bin products actively supplied into a regulated prescription market. Its commercial revenues are currently anchored in Australia, where the Therapeutic Goods Administration (TGA) has rescheduled both compounds to Schedule 8, enabling psychiatrist-led prescribing for PTSD and treatment-resistant depression (TRD). As of Q1 2026, OPTH has shipped over 6K doses, supplying sufficient product for more than 500 patients through Australia's Authorised Prescriber Scheme. In May 2026, the company completed a $15M oversubscribed public offering alongside its Nasdaq uplisting, materially strengthening its balance sheet and extending its execution runway as commercialization scales. Silicon Valley Spotlight
Tech leaders have helped bring broader attention to the category. 
Interest in ps-ych-ede-lic compounds has increasingly moved into the mainstream. Over the years, several well-known technology leaders, including Apple cofounder Steve Jobs and OpenAI CEO Sam Altman, have publicly discussed their experiences with ps-ych-ede-lic substances, while entrepreneurs such as Bryan Johnson have recently brought additional attention to the category. Elon Musk and Google cofounder Sergey Brin have also been mentioned in media coverage surrounding mi-cro-do-sing, further illustrating how visible the topic has become across technology and business circles. While these individuals have no connection to OPTH, their public comments and media attention highlight the growing visibility of ps-ych-ede-lic-related discussions across technology, healthcare, and business communities. Why OPTH Is On Our Radar
A Fast-Growing Market With Limited GMP-Certified SuppliersThe global ps-ych-ede-lic therapeutics market is forecast to grow over 260% — from approximately $3.41B in 2026 to approximately $12.4B within the next decade. 
Within that, the ps-ych-ede-lic active pharma ingredient (API) market alone is projected to reach $15–17B by the early-to-mid 2030s, implying a CAGR of 15.2%. Most of that value flows to upstream, GMP-certified manufacturers — exactly the position OPTH occupies. While peers like Compass Pathways ($1.65B market cap) and AtaiBeckley ($1.58B) remain pre-commercial, according to the Diamond Equity Research report, OPTH is already generating pharma revenues from two indications in a live reimbursed market. Commercial Traction in Australia — With Expanding AccessAustralia is the world's most advanced commercial market for prescribed Psi-locy-bin and M-D-M-A. OPTH's M-D-M-A shipments have scaled from 160 doses in September 2024 to 1,000-dose repeat orders through February 2026. The company's Psi-locy-bin products entered the Australian market in August 2025 and are already included in Medibank's insurance-backed psychotherapy program — Medibank being Australia's largest private health insurer. On May 29, 2026, the TGA issued updated Authorised Prescriber recommendations that broaden therapist eligibility and accept a wider range of treatment settings, potentially expanding OPTH's addressable clinic base. On June 2, 2026, OPTH completed a commercial Psi-locy-bin production run of 5mg capsules for TRD — with additional product earmarked for planned clinical trials in the United States and Europe. Coverage Begins
Diamond Equity Research recently initiated coverage and outlined its valuation framework.In May, Diamond Equity Research initiated coverage with a target of C$15.00 per share — representing approximately 89% potential upside from the C$7.95 range at the time of the report. The DCF-based valuation uses a WACC of 10.91% and a 2.0% terminal growth rate, modeling Australia as the primary revenue driver. Analyst Hunter Diamond, CFA, projects long-term gross margins of approximately 75%, driven by the company's largely fixed-cost GMP infrastructure and protocol-defined dosing.. Management estimates EBITDA breakeven at approximately 1,000 patients per month — with current utilization well below 1% of installed capacity. 8 Reasons Why OPTH is Topping Our Watchlist This Morning—Wednesday, July 1, 2026…
1. Small Float: With fewer than 5M shares listed as available to the public, OPTH’s small float could witness the potential for big moves if demand begins to shift. 2. Analyst Coverage: OPTH recently received coverage from Diamond Equity Research, adding another layer of analyst coverage as commercialization continues to advance. 3. Commercial Momentum: OPTH has issued five material announcements since June began, including international shipments, new product launches, and continued commercial execution in Australia. 4. Global Shipments: OPTH has completed commercial psi-locy-bin shipments to Australia, supplied product for a planned Phase 2 clinical trial in the United Kingdom, and continues expanding its international distribution footprint. 5. Licensed Infrastructure: OPTH operates GMP-certified manufacturing facilities with Health Canada licenses supporting cultivation, formulation, encapsulation, quality control, and international distribution from a vertically integrated platform. 6. Commercial Market: OPTH is already supplying regulated prescription markets in Australia, where its products are being prescribed to eligible patients and reimbursed by four major public and private payers. 7. Production Capacity: OPTH has installed manufacturing capacity of approximately 1M M-D-M-A capsules and 1M psi-locy-bin capsules annually without requiring incremental capital expenditure, providing room to support future demand. 8. Market Growth: The global ps-ych-ede-lic therapeutics market is forecast to grow over 260% — from approximately $3.41B in 2026 to approximately $12.4B within the next decade — creating a broader industry backdrop for OPTH’s regulated manufacturing and commercial supply platform. Take a Look At (OPTH) While It’s Still Early…
From a small public float and recent analyst coverage to expanding commercial shipments, licensed GMP infrastructure, regulated prescription market activity, and established production capacity, OPTH continues checking several boxes that have our attention this morning. Add to that a global ps-ych-ede-lic therapeutics market forecast to grow more than 260%—from approximately $3.41B in 2026 to approximately $12.4B within the next decade—alongside a U.S. Executive Order accelerating FDA review of ps-ych-ede-lic therapies, and it is easy to see why OPTH is on our radar today. We have all eyes on OPTH right now. Take a look at OPTH while it’s still early Also, keep a look out for my next update—it could be here very shortly. Sincerely, Paul Prescott
Co-Founder & Managing Editor
Street Ideas Newsletter |
